Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice

Leukemia Research

Volumn 29, Issue 3, 2005, Pages 331-341

  Vallera, Daniel A ^a   Todhunter, Deborah ^a   Kuroki, David W ^a   Shu, Yanqun ^a   Sicheneder, Andy ^a   Panoskaltsis Mortari, Angela ^a   Vallera, Vincent D ^a   Chen, Hua ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Animal model; Anti CD3 sFv; Anti human T cell; diphtheria toxin; Fusion protein; Human anti cancer agent; Immunotoxin; Leukemia

Indexed keywords

DIPHTHERIA TOXIN; HYBRID PROTEIN; IMMUNOTOXIN; IMMUNOTOXIN CD3; MONOCLONAL ANTIBODY CD3; PROTEIN BIC3; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HEAVY CHAIN; IC 50; LEUKEMIA CELL; LIGHT CHAIN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T CELL LEUKEMIA; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; KIDNEY; LEUKEMIA, T-CELL; MICE; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 12344336320     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.08.006     Document Type: Article

References (38)

1. R.J. Kreitman Recombinant fusion toxins for cancer treatment Expert Opin Biol Ther 2 2002 785 791
2. F. Himmelweit F. Himmelweit The collected papers of Paul Erlich, vol. 3 1960 Pergamon New York
3. L. Chatenoud, and J.F. Bach Anti-CD3 antibodies Immunol Ser 59 1993 175 191
4. M. Yamaizumi, E. Mekada, T. Uchida, and Y. Okada One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell Cell 15 1978 245 250
5. R.J. Collier Diphtheria toxin: mode of action and structure Bacteriol Rev 39 1975 54 85
6. N.J. Oppenheimer, and J.W. Bodley Diphtheria toxin. Site and configuration of ADP-ribosylation of diphthamide in elongation factor 2 J Biol Chem 256 16 1981 8579 8581
7. D.P. Williams, C.E. Snider, T.B. Strom, and J.R. Murphy Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells J Biol Chem 265 1990 11885 11889
8. R.J. Youle, F.M. Uckun, D.A. Vallera, and M. Colombatti Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen J Immunol 136 1986 93 98
9. A.H. Filipovich, D.A. Vallera, R.J. Youle, R.R. Quinones, D.M. Neville Jr., and J.H. Kersey Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease Lance 1 1984 469 472
10. D.A. Vallera, A. Panoskaltsis-Mortari, C. Jost, S. Ramakrishnan, C.R. Eide, and R.J. Kreitman Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor Blood 88 1996 2342 2353
11. D.A. Vallera, A. Panoskaltsis-Mortari, and B.R. Blazar Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin Protein Eng 10 1997 1071 1076
12. D.A. Vallera, D.W. Kuroki, A. Panoskaltsis-Mortari, D.J. Buchsbaum, B.E. Rogers, and B.R. Blazar Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model Blood 96 2000 1157 1165
13. J. Thompson, S. Stavrou, M. Weetall, J.M. Hexham, M.E. Digan, and Z. Wang Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion Protein Eng 14 2001 1035 1041
14. M. Whitlow, B.A. Bell, S.L. Feng, D. Filpula, K.D. Hardman, and S.L. Hubert An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability Protein Eng 6 1993 989 995
15. P.C. Beverley, and R.E. Callard Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody Eur J Immunol 11 1981 329 334
16. J.L. Li, G.L. Shen, M.A. Ghetie, R.D. May, M. Till, and V. Ghetie The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies Cell Immunol 118 1989 85 99
17. P.G. Kasprzyk, S.U. Song, P.P. Di Fiore, and C.R. King Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies Cancer Res 52 1992 2771 2776
18. J.K. Batra, P.G. Kasprzyk, R.E. Bird, I. Pastan, and C.R. King Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin Proc Natl Acad Sci USA 89 1992 5867 5871
19. G.L. Shen, J.L. Li, M.A. Ghetie, V. Ghetie, R.D. May, and M. Till Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas Int J Cancer 42 1988 792 797
20. S. Menard, S.M. Pupa, M. Campiglio, and E. Tagliabue Biologic and therapeutic role of HER2 in cancer Oncogene 22 2003 6570 6578
21. J.M. Pagel, D.C. Matthews, F.R. Appelbaum, I.D. Bernstein, and O.W. Press The use of radioimmunoconjugates in stem cell transplantation Bone Marrow Transp 29 2002 807 816
22. I. Kurucz, J.A. Titus, C.R. Jost, and D.M. Segal Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies Mol Immunol 32 1995 1443 1452
23. C.H. Chan, B.R. Blazar, C.R. Eide, and R.J. Kreitman Vallera DA: A murine cytokine toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells Blood 86 1995 2732
24. D.A. Vallera, L.J. Burns, A.E. Frankel, A.R. Sicheneder, R. Gunther, and K. Gajl-Peczalska Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies J Immunol Methods 197 1996 69 83
25. B.R. Blazar, P.A. Taylor, A. Panoskaltsis-Mortari, T.A. Barrett, J.A. Bluestone, and D.A. Vallera Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens Blood 87 1996 827 837
26. D. Abramowicz, L. Schandene, M. Goldman, A. Crusiaux, P. Vereerstraeten, and L. De Pauw Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients Transplantation 47 1989 606 608
27. V. Flamand, D. Abramowicz, M. Goldman, C. Biernaux, G. Huez, and J. Urbain Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo J Immunol 144 1990 2875 2882
28. C. Ferran, K. Sheehan, M. Dy, R. Schreiber, S. Merite, and P. Landais Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation Eur J Immunol 20 1990 509 515
29. J. Quintans, A. Yokoyama, B. Evavold, R. Hirsch, and R.D. Mayforth Related direct activation of murine resting T cells by con A or anti-CD3 Ig J Mol Cell Immunol 4 1989 225 235
30. J. Thompson, S. Stavrou, M. Weetall, J.M. Hexham, M.E. Digan, and Z. Wang Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion Protein Eng 14 2001 1035 1041
31. R.J. Youle, F.M. Uckun, D.A. Vallera, and M. Colombatti Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen J Immunol 136 1986 93 98
32. B.R. Blazar, P.A. Taylor, P.S. Linsley, and D.A. Vallera In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibillity complex (MHC) barrier in mice Blood 83 1994 3815
33. J.K. Kim, M.F. Tsen, V. Ghetie, and E.S. Ward Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice Scand J Immunol 40 1994 457 465
34. J.K. Batra, S. Kasturi, M.G. Gallo, R.L. Voorman, S.M. Maio, and V.K. Chaudhary Insertion of constant region domains of human IgG1 into CD4-PE40 increases its plasma half-life Mol Immunol 30 1993 379 386
35. M. Weetall, M.E. Digan, R. Hugo, S. Mathew, C. Hopf, and N. Tart-Risher T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice Transplantation 73 2002 1658 1666
36. Y.V. van Oosterhout, J.L. van Emst, H.H. Bakker, F.W. Preijers, A.V. Schattenberg, and D.J. Ruiter Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study Int J Pharm 221 2001 175 186
37. C.A. Huang, K. Yamada, M.C. Murphy, A. Shimizu, R.B. Colvin, and D.M. Neville Jr. In vivo T cell depletion in miniature swine using the swine CD3 immunotoxin, pCD3-CRM9 Transplantation 68 1999 855 860
38. B. Clinchy, and E.S. Vitetta The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice J Immunol Methods 218 1998 141 153